UOC
UBS O'Connor Portfolio holdings
AUM
$1.93B
1-Year Return
38.75%
This Quarter Return
+5.87%
1 Year Return
+38.75%
3 Year Return
+182.42%
5 Year Return
+480.25%
10 Year Return
+1,573.29%
AUM
$4.01B
AUM Growth
+$484M
(+14%)
Cap. Flow
+$336M
Cap. Flow
% of AUM
8.39%
Top 10 Holdings %
Top 10 Hldgs %
56.46%
Holding
586
New
87
Increased
121
Reduced
176
Closed
112
Top Buys
| 1 |
Kellanova
K
|
$305M |
| 2 |
SRCL
Stericycle Inc
SRCL
|
$145M |
| 3 |
MRO
Marathon Oil Corporation
MRO
|
$104M |
| 4 |
CHX
ChampionX
CHX
|
$98.2M |
| 5 |
Spirit AeroSystems
SPR
|
$90.4M |
Top Sells
| 1 |
ETRN
Equitrans Midstream Corporation Common Stock
ETRN
|
$149M |
| 2 |
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
|
$81.8M |
| 3 |
SWN
Southwestern Energy Company
SWN
|
$56.7M |
| 4 |
Union Pacific
UNP
|
$24.2M |
| 5 |
X
US Steel
X
|
$18.7M |
Sector Composition
| 1 | Energy | 21.14% |
| 2 | Technology | 19.82% |
| 3 | Healthcare | 14.53% |
| 4 | Industrials | 11.25% |
| 5 | Consumer Staples | 9.11% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
SPKL
301
Spark I Acquisition Corp
SPKL
$94.8M
| $702K | 0.02% |
66,832
-2,159
| -3% | -$22.7K |
|
302
Dyne Therapeutics
DYN
$2.02B
| $694K | 0.02% |
19,318
-13,626
| -41% | -$489K |
|
303
DiamondRock Hospitality
DRH
$1.76B
| $690K | 0.02% |
+79,007
| New | +$690K |
|
304
Zscaler
ZS
$42.7B
| $684K | 0.02% |
+4,000
| New | +$684K |
|
305
Arvinas
ARVN
$575M
| $675K | 0.02% |
27,403
-2,898
| -10% | -$71.4K |
|
|
ITOS
306
DELISTED
iTeos Therapeutics
ITOS
| $673K | 0.02% |
65,940
+30,617
| +87% | +$313K |
|
|
VRNA
307
Verona Pharma
VRNA
$9.2B
| $649K | 0.02% |
+22,541
| New | +$649K |
|
308
Skillsoft
SKIL
$132M
| $646K | 0.02% |
41,692
| – | – |
|
309
Mirum Pharmaceuticals
MIRM
$3.82B
| $645K | 0.02% |
16,538
-21,550
| -57% | -$840K |
|
310
Xencor
XNCR
$610M
| $644K | 0.02% |
+32,000
| New | +$644K |
|
|
NARI
311
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $623K | 0.02% |
+15,100
| New | +$623K |
|
312
Annaly Capital Management
NLY
$14.2B
| $614K | 0.02% |
+30,591
| New | +$614K |
|
313
Affirm
AFRM
$28.4B
| $612K | 0.02% |
15,000
+500
| +3% | +$20.4K |
|
314
Vaxcyte
PCVX
$4.29B
| $606K | 0.02% |
5,307
-1,000
| -16% | -$114K |
|
315
Context Therapeutics
CNTX
$73.6M
| $605K | 0.02% |
308,758
+15,000
| +5% | +$29.4K |
|
316
Q32 Bio
QTTB
$20.4M
| $590K | 0.01% |
13,229
+1,229
| +10% | +$54.8K |
|
317
Aligos Therapeutics
ALGS
$78.8M
| $581K | 0.01% |
67,096
+27,096
| +68% | +$235K |
|
318
Boston Scientific
BSX
$159B
| $572K | 0.01% |
6,827
-273
| -4% | -$22.9K |
|
319
Acrivon Therapeutics
ACRV
$41.8M
| $555K | 0.01% |
79,249
-26,000
| -25% | -$182K |
|
320
Edgewise Therapeutics
EWTX
$1.64B
| $534K | 0.01% |
20,000
-65,008
| -76% | -$1.74M |
|
321
Schrodinger
SDGR
$1.41B
| $525K | 0.01% |
28,316
+8,305
| +42% | +$154K |
|
322
EPR Properties
EPR
$4.05B
| $510K | 0.01% |
10,400
-1,800
| -15% | -$88.3K |
|
|
ALLK
323
DELISTED
Allakos
ALLK
| $508K | 0.01% |
777,702
+61,137
| +9% | +$39.9K |
|
324
Merus
MRUS
$5.1B
| $496K | 0.01% |
9,922
+922
| +10% | +$46.1K |
|
325
Arcus Biosciences
RCUS
$1.3B
| $487K | 0.01% |
31,862
-33,325
| -51% | -$510K |
|